TNFSF13 and rheumatoid arthritis: RA patients who received Atacicept (a biological agent that blocks the combination of BAFF/APRIL and TACI) showed a significant reduction in serum anti-RF levels, but in phase II clinical trials, Atacicept did not show significant clinical improvement compared with the placebo group (136).